Clinical trials for Prostate cancer

150 currently recruiting clinical trials
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06653777 #2024-512729-10-00
Locally Advanced Metastatic Metastatic Castration-resistant FGFR 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant BRAF 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant EGFR MET NTRK-1/2/3 RET ROS-1 Other mutation 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer #NCT05732831 #2022-502645-99-00
Locally Advanced Metastatic Metastatic Castration-resistant MTAP 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Tango Therapeutics
Phase 2 Prostate cancer #NCT02861573 #2023-506987-15-00
Neuroendocrine tumor Metastatic Hormone-sensitive Metastatic Castration-resistant Systemic Treatment-Naive Chemotherapy Hormone therapy
Immunotherapy Immunotherapy
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Prostate cancer #NCT06991556 #2024-520156-22-00
Adenocarcinoma Metastatic Hormone-sensitive Systemic Treatment-Naive
Chemotherapy Targeted therapy Antibody Drug Conjugates (ADC) Radiotherapy Internal Vectorised Radiotherapy (IVR)
4 recruiting sites
Novartis
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT05503797 #2024-513578-23-00
Neuroendocrine tumor Locally Advanced Metastatic BRAF 1 2 3 or more
HRAS KRAS G12C KRAS non G12C NRAS Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00
Locally Advanced Metastatic BRAF 1 2 3 or more
KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics